A Randomized Clinical TrialLiqiang Zheng, MD, PhD1,2,3; Li Gai, MD4,5; Yani Wu, BS3; et alChaonan
既往的试验表明,与化学免疫治疗相比,不可逆 BTK 抑制剂伊布替尼(I)和BCL-2抑制剂维奈克拉(V)可改善 CLL 结局。I 和 V 靶向 CLL 的两个关键病理生理通路,具有协同作用。这得到
Aris, PhD1; Wei Perng, PhD2,3; Dana Dabelea, MD, PhD2,3,4; et alAmy M. Padula, PhD5; Akram
Hauspurg, MD, MS1,2; Kripa Venkatakrishnan, MPH3; Latima Collins, MD2; et alMalamo Countouris, MD
The Pros and Cons of Viral Testing: How to Risk- May 21, 2024Claire Castellano, MD, MPH, Pediatrics
Schuermans, BSc1,2,3; Buu Truong, MD1,2; Maddalena Ardissino, MBBS4,5; et alRohan Bhukar, MS1,2;
ichi Nagakura, MD, PhD1,2; Sakura Sato, MD3; Wakako Shinahara, MS4; et alHiroshi Kido, MD, PhD4;
Pellegrino, MD1,2; Patrizia Papacci, MD3,4; Flavia Beccia, MD3,4; et alFrancesca Serrao, MD3;
仅用于向医疗卫生专业人士提供科学信息,不代表平台立场审批编码:PP-IX-CN-4047 获批日期:2024年5月24日参考文献[1]https://immunology.knowledgehub
Wang, PhD, MS1; Gowtham Asokan, MS2; Jukka-Pekka Onnela, DSc2; et alDonna D. Baird, PhD3; Anne
Bellai-Dussault, MSc1,2,3; Shelley D. Dougan, MSc2,3; Deshayne B. Fell, PhD1,3; et alJulian Little